Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $9.51B
• Dividend Yield: 0.53%
• Average Volume (3M): 2.30M
• Price to Earnings (P/E): 133.0
• Beta (1Y): 0.91
• Revenue Growth: 3.85%
• EPS Growth: -48.16%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.42
• Shares Outstanding: 155,693,440
• 10 Day Avg. Volume: 1,892,399
• 30 Day Avg. Volume: 2,303,988
• PEG Ratio: -1.97
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 6.64
• P/FCF Ratio: 31.59
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 7.35
• Enterprise Value/Gross Profit: 11.25
• Enterprise Value/Ebitda: 45.45
• 1Y Price Target: $68.38
• Price Target Upside: 17.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $63.00 ▲(8.28% Upside)

Bio-Techne's overall stock score is driven by its financial stability and technical indicators, despite challenges in revenue growth and high valuation. The earnings call provides some optimism with margin improvements and geographic growth, but the high P/E ratio and low dividend yield are significant concerns.

Positive Factors

Large Pharma Growth

The growth in revenue from large pharmaceutical customers indicates strong demand for Bio-Techne's products, which supports long-term revenue stability and expansion in a key market segment.

China Market Expansion

Continued growth in the Chinese market enhances Bio-Techne's global presence and taps into a rapidly expanding market, providing a durable growth opportunity.

Margin Expansion

The expansion of operating margins reflects improved operational efficiency, which can lead to sustained profitability and financial health over the long term.

Negative Factors

Organic Revenue Decline

A decline in organic revenue indicates challenges in maintaining growth momentum, which could affect future revenue stability and market competitiveness.

Biotech Funding Challenges

Persistent funding challenges in the biotech sector may limit Bio-Techne's growth opportunities and affect its ability to capitalize on emerging biotech innovations.

Protein Sciences Segment Decline

Declines in the Protein Sciences segment suggest potential issues in a core business area, which could impact overall revenue and market positioning if not addressed.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation (TECH) is a leading global supplier of life science reagents and instruments, primarily serving the pharmaceutical and biotechnology sectors, as well as academic research institutions. The company operates through two main segments: the Protein Platforms segment, which includes a wide array of proteins, antibodies, and reagents used for research and diagnostic applications; and the Diagnostics segment, which offers a range of products for molecular diagnostics and protein analysis. Bio-Techne is known for its innovative solutions that support the development of new therapeutics and diagnostic tests.

How the Company Makes Money

Bio-Techne generates revenue through multiple streams, primarily from the sale of reagents, instruments, and diagnostic products. The Protein Platforms segment is a significant contributor to the company's earnings, as it provides essential research tools that are in high demand within the life sciences community. Additionally, the Diagnostics segment offers products that cater to the growing field of molecular diagnostics, contributing to recurring revenue from both product sales and potential partnerships with clinical laboratories. Bio-Techne also engages in strategic collaborations with other companies and research institutions, enhancing its market presence and expanding its product offerings, which further drives revenue. The company benefits from a strong customer base, including major pharmaceutical companies, which rely on Bio-Techne's products for drug development and testing.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne maintains a stable financial position with strong cash flow generation and prudent leverage. However, declining profitability margins and inconsistent revenue growth pose challenges. The company needs to address operational inefficiencies to improve overall financial performance.

Income Statement

Bio-Techne's revenue growth has been inconsistent, with a significant drop in growth rate in the latest year. Gross profit margin remains strong, but net profit margin has decreased, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also declined, suggesting pressure on operational profitability.

Balance Sheet

The company maintains a healthy debt-to-equity ratio, indicating prudent leverage management. However, return on equity has decreased, reflecting lower profitability. The equity ratio is stable, showing a solid capital structure.

Cash Flow

Operating cash flow remains robust, with a strong coverage ratio. Free cash flow growth is positive, though it has slowed down. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.22B	1.22B	1.16B	1.14B	1.11B	931.03M
Gross Profit	795.37M	790.27M	769.73M	769.82M	756.50M	632.85M
EBITDA	196.86M	216.88M	310.37M	460.56M	420.12M	258.47M
Net Income	77.98M	73.40M	168.10M	285.26M	272.05M	140.41M
Balance Sheet
Total Assets	2.53B	2.56B	2.70B	2.64B	2.29B	2.26B
Cash, Cash Equivalents and Short-Term Investments	144.96M	162.19M	152.86M	204.31M	247.03M	231.55M
Total Debt	380.70M	444.06M	419.54M	454.96M	325.97M	420.55M
Total Liabilities	536.52M	639.06M	635.02M	672.18M	593.79M	691.72M
Stockholders Equity	1.99B	1.92B	2.07B	1.97B	1.70B	1.57B
Cash Flow
Free Cash Flow	224.06M	256.55M	236.10M	216.15M	280.36M	307.86M
Operating Cash Flow	251.25M	287.56M	298.98M	254.39M	325.27M	352.16M
Investing Cash Flow	-12.89M	-35.18M	-203.03M	-265.65M	-96.85M	-243.52M
Financing Cash Flow	-286.54M	-253.91M	-122.40M	22.62M	-242.85M	-62.55M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 58.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 58.18 is below the 20-day moving average (MA) of 61.83, above the 50-day MA of 57.57, and above the 200-day MA of 56.37, indicating a neutral trend. The MACD of 0.67 indicates Positive momentum. The RSI at 42.25 is Neutral, neither overbought nor oversold. The STOCH value of 29.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	78 Outperform	$8.00B	14.36	124.50%	―	31.19%	59.01%
CORT	72 Outperform	$7.48B	87.58	16.47%	―	17.92%	-26.13%
JAZZ	68 Neutral	$8.36B	―	-9.06%	―	4.14%	-179.96%
TECH	61 Neutral	$9.51B	133.03	3.80%	0.53%	3.85%	-48.16%
ROIV	58 Neutral	$13.57B	―	-15.84%	―	-85.32%	-111.82%
RYTM	52 Neutral	$7.01B	―	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bio-Techne Corporate Events

Bio-Techne Reports Q1 2026 Revenue and EPS Growth

At its annual meeting, Bio-Techne Corporation announced the election of nine directors and the approval of executive compensation and KPMG LLP as its independent auditor for fiscal year ending June 30, 2026. The company reported a slight decrease in first-quarter fiscal 2026 revenue to $286.6 million, with a GAAP EPS increase to $0.24. The divestiture of Exosome Diagnostics and cost initiatives improved operating margins. Despite challenges in the emerging biotech sector, Bio-Techne saw stabilization in the US academic market and growth in its ProteinSimple and Spatial Biology segments. The company remains focused on its strategic growth pillars, including cell therapy, where some customers received FDA Fast Track Designation.

The most recent analyst rating on (TECH) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.

Bio-Techne Reports Solid Q4 2025 Results Amid Strategic Shift

Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding scientific investigations and drug discovery efforts. With a diverse product portfolio, the company serves the biopharma and academic research communities worldwide.

Bio-Techne’s Earnings Call: Growth Amid Challenges

Bio-Techne’s recent earnings call painted a picture of solid organic growth and strategic positioning in core markets, particularly in biopharma and cell therapy. Despite these strengths, the company remains cautious due to uncertainties in academic funding, challenges in the biotech market, and policy-related headwinds.

Bio-Techne Divests Exosome Diagnostics to Boost Growth

Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a 3% organic revenue increase to $317.0 million and a full-year organic revenue growth of 5% to $1.2 billion. Despite a decrease in GAAP EPS to ($0.11) from $0.25 a year ago, adjusted EPS rose to $0.53 from $0.49. The company announced the divestiture of its Exosome Diagnostics business to focus on high-growth areas, which is expected to enhance profitability. The Protein Sciences segment showed strong growth, while the Diagnostics and Spatial Biology segment faced challenges due to unfavorable product mix.

The most recent analyst rating on (TECH) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.